BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)
Supplemental material
Ann Rheum Dis
Supplementary Table 5. Patient-reported outcomes among patients with PASC following breakthrough versus non-breakthrough COVID-19 infection Characteristic p-value
All patients with PASC (N=137)
PASC following breakthrough COVID-19 infection (N=48)
PASC following non- breakthrough COVID-19 infection (N=89)
Pain (SF-MPQ) N
124
45
79
Median score [IQR]
7 (3, 12)
6 (2, 13)
7 (3, 11)
0.74
Pain rating index ordinal categories, n (%)
0.32
No pain
12 (9)
2 (4)
10 (11)
Mild pain
31 (23)
13 (27)
18 (20)
Discomforting, distressing, horrible, or excruciating pain
83 (61)
30 (63)
53 (60)
Fatigue (FSI) N
128
45
83
Median score [IQR]
67 (36, 90.5)
66 (33, 89)
67 (36, 92)
0.66
Functional status (mHAQ) N
129
45
84
Median score [IQR]
0.4 (0.0, 0.8)
0.3 (0.1, 0.8)
0.4 (0.0, 0.7)
0.32
Functional status categorical score, n (%)
0.85
Normal (<0.3)
64 (47) 65 (47)
23 (48) 22 (46)
41 (46) 43 (48)
Mild, moderate, or severe (0.3 to >1.8) Health status (SF-12) Physical Component Summary (PCS-12) score, median [IQR] Mental Component Summary (MCS-12) score, median [IQR] Persistent symptoms at time of survey, n (%) Fatigue/malaise
38.3 (31.4, 47.4)
37.6 (31.5, 46.1)
38.8 (31.2, 48.1)
0.70
46.4 (38, 54.9)
45.5 (39.5, 54.0)
46.8 (36.7, 55.8)
0.63
39 (28)
16 (33)
23 (26)
0.43
Anosmia
25 (18) 22 (16)
6 (13) 5 (10)
19 (21) 17 (19)
0.25 0.23
Dysgeusia
Dyspnea and/or cough
15 (11)
4 (8)
11 (12)
0.57
Nasal congestion or rhinorrhea
17 (12)
8 (17)
9 (10)
0.29
2022;0:1–9. doi: 10.1136/ard-2022-223439 Ann Rheum Dis , et al. Patel NJ
Powered by FlippingBook